Abstract. In the present study, we aimed to demonstrate whether praline-rich tyrosine kinase-2 (Pyk2) participates in the chemokine receptor 7 (CCR7) downstream signaling network, and to determine the role of this molecule and the related mechanism in the CCR7-mediated regulation of viability and metastasis in vivo and in vitro of squamous cell carcinoma of the head and neck (SCCHN). We constructed the stable Pyk2 related non-kinase (PRNK)-expressing SCCHN cell line, and examined the viability, apoptosis, migration, invasion and adhesion ability in the transfected and untransfected SCCHN cells. An SCCHN tumor model in nude mice was designed and the tumor growth rate was assayed. E-cadherin and vimentin expression was assessed when Pyk2 was inactivated. We found that the stable PRNKexpressing SCCHN cells exhibited low viability, a high rate of apoptosis, low migratory ability, low invasive ability and low adhesion capacity. In the nude mouse body, the tumors formed by these cells grew slowly when compared to the tumor growth in the control group. When Pyk2 was inactivated, CCR7-induced E-cadherin and vimentin expression levels were altered. Thus, Pyk2 is a key downstream signaling molecules of CCR7 in SCCHN, which promotes SCCHN tumorigenesis and progression.
Introduction
Squamous cell carcinoma of the head and neck (SCCHN), a malignant tumor of epithelial origin, accounts for more than 90% of all head and neck cancers, with a 5-year survival rate of only ~30-40% (1) . The main reasons for the poor diagnosis of this disease are tumor recurrence and metastasis to lymph nodes. Therefore, a better understanding of the processes involved in its recurrence and metastasis is necessary to enable the development of therapies designed to prevent tumor dissemination.
Chemokines are a group of small structurally related molecules that constitute a superfamily of inducible secreted proinflammatory proteins that are involved in a variety of immune responses (2) (3) (4) (5) . In has been reported that the CC chemokine CCL19 and its receptor chemokine receptor 7 (CCR7) participate in the metastasis of various types of tumors, such as uveal melanoma, pancreatic ductal adenocarcinoma and gastric cancer, in a manner such as 'lymphocyte homing' (6) (7) (8) . Our previous studies demonstrated that CCR7 can regulate cell migration and invasion of SCCHN, and this process involves several signaling pathways including PI3K/cdc42, MAPK and JAK2/STAT3 (9) (10) (11) .
In a previous study, we also found that praline-rich tyrosine kinase-2 (Pyk2) is activated by CCL19-CCR7 interaction in SCCHN cells, and the Pyk2 inhibitor inhibits tumor cell mobility (12) . The results suggest that Pyk2 may be involved in the CCR7-mediated regulation of SCCHN cell biological activity. The aim of the present study was to further demonstrate whether Pyk2 participates in the CCR7 downstream
The role of Pyk2 in the CCR7-mediated regulation of metastasis and viability in squamous cell carcinoma of the head and neck cells in vivo and in vitro signaling network, and to determine whether this molecule plays a role in the CCR7-mediated regulation of SCCHN viability and metastasis in vivo and in vivo and the involved mechanisms.
Materials and methods
Cell lines. PCI-4B and PCI-37B, well-characterized SCCHN cell lines derived from the metastatic lymph node of SCCHN patients, were kindly donated by the university of Pittsburgh Cancer Institute (13, 14) . The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, uSA) containing 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, uSA), 100 u/ml penicillin G and 100 u/ml streptomycin.
Reagents and antibodies. CCL19-and CCR7-specific monoclonal antibodies (mouse anti-human CCR7 antibody) were purchased from R&D Systems (Minneapolis, MN, uSA). Anti-Pyk2 and anti-phospho-Pyk2 were purchased from Santa Cruz Biotechnology (Dallas, TX, uSA). Antivimentin and anti-E-cadherin were purchased from Cell Signaling Technology (Danvers, MA, uSA). The treatment conditions, such as concentration and time, were drawn from pre-experiments.
CCR7 siRNA and PRNK transfection. The Pyk2 related non-kinase (PRNK) is a recently described isoform of Pyk2 that encodes part of the COOH-terminal domain of Pyk2 and has been proposed to selectively downregulate Pyk2 function (15) . Lentiviruses containing the PRNK gene (LV-PRNK-EGFP) or a negative control (Lenti-EGFP) were obtained from Shanghai GeneChem, China. The construction of PRNK recombinant lentiviral vectors was as follows. The GV218 vector (Lenti-EGFP; purchased from Shanghai GeneChem) was linearized with BamHI and AgeI. The PRNK gene cDNA sequence was as described by Xiong et al (15) , and synthesized and purchased from Shanghai GeneChem. Migration assay. Disposable 24-well Transwell inserts with a 80-µm pore size were run in triplicate in DMEM with 0.5% (w/v) BSA. CCL19 was added to the lower chamber at a concentration of 500 ng/ml. Cell suspensions (2x10 5 ) were placed in the top of the inserts. After 24 h of incubation, the cells on the upper surface of the inserts were removed with a cell harvester, and the membrane was washed with medium. Cells that penetrated the membrane were fixed with ice-cold methanol, stained with 0.5% crystal violet, photographed and counted under a microscope. Migration index was calculated based on the control involving random migration.
Matrigel invasion assay.
Cell invasion was quantified in vitro using Matrigel-coated semi-permeable, modified inserts with a pore size of 8-µm. The analysis of the Matrigel invasion assay was performed as described in the migration assay incubated with CCL19 for 36 h. Invasion index was calculated based on the control involving random invasion.
Viability assay. The viability assay is a colorimeter assay that relies on the ability of viable cells to convert a soluble tetrazolium salt, MTT, into a quantifiable insoluble formazan precipitate (yellow to purple color change). Cell death correlates with reduced purple precipitate formation. In brief, SCCHN cells were plated into a 96-well plate at an initial density of 5x10 4 cells/well. Confluent cells (70-80%) were serum starved for 24 h, and then treated with CCL19. Media were discarded, and 20 µl of MTT (5 µg/ml in PBS) was added for 4 h. DMSO (200 µl) was then added to each well, and the plate was incubated at 37˚C in a 5% CO 2 atmosphere for 1 h to lyse all of the cells, and the media were collected for measurement. The optical density (OD) was read by a spectrometer (Tecan, Männedorf, Switzerland) at 490 nm. The percentage of cell viability was calculated as follows: Viability percentage (%) = (OD of treatment group)/(OD of control group) x 100%.
Adhesion assay. For the assay, 96-well plates (Corning Costar, Cambridge, MA, uSA) were coated with fibronectin or left uncoated, and incubated at room temperature overnight. SCCHN cells were plated in an initial density of 1x10 4 cells/well, and inbubated at 37˚C for 1.5 h, and then washed with phosphate-buffered saline (PBS) three times. MTT (20 µl, 5 µg/ml) was added for 4 h, and then dimethylsulphoxide (DMSO; Sigma, uSA) was added to each well to lyse all cells for 1 h at 37˚C at 5% CO 2 . The OD was read on a spectrometer (Tecan) through a 490-nm filter. For each experimental condition 8 wells were analyzed in parallel. Adhesion index (%) = [(fibronectin conditions cell OD/control conditions cell OD) -1] x 100%.
Apoptosis assay. To determine the role of the Pyk2 pathway in apoptosis, Annexin V and propidium iodide (PI) staining was performed. Briefly, the transfected cells were pretreated and harvested at the indicated time points. Cells were stained with fluorescein isothiocyanate (FITC)-conjugated Annexin V and PI according to the manufacturer's recommendation. In these experiments, the cells that were apoptotic were those that were Annexin V-positive/PI-negative. Samples were analyzed using a FACSCalibur flow cytometer and CellQuest software (BD, Sparks, MD, uSA).
Xenograft studies of nude mice. BALB/c athymic nude mice (4 weeks of age) were maintained under standard laboratory conditions on a 12-h light-dark cycle and given access to sterilized food and water ad libitum under a specific pathogen-free environment. For the subcutaneous injection, the cells (1x10 6 ) were suspended in 200 µl PBS and then inoculated subcutaneously into the right breast region of the BALB/c nude mice. Each group consisted of six nude mice. Two-dimensional measurements were taken with an electronic caliper, and the tumor volume in mm 3 was calculated using the formula: Volume = a x b 2 x 0.52, where a is the longest diameter; b is the shortest diameter. At the terminal point when the mice were sacrificed, the tumors were fixed in 10% formalin overnight and subjected to routine histological examination. All of the animals were treated according to the protocols approved by the Institutional Animal Care and use Committee of China Medical university.
Statistical analysis. Data are expressed as the mean ± standard deviation (SD) of repeated assays. Significant differences between the two groups were evaluated using an unpaired Student's t-test. A p-value <0.05 was considered to indicate a statistically significant result. All statistical analyses were performed with software SPSS 11.0 (SPSS, Inc., Chicago, IL, uSA).
Results

PRNK transfection and its role in Pyk2.
PRNK is the C-terminal non-kinase region of Pyk2. It is characterized as a splice variant form of Pyk2. PRNK will interact with several of the Pyk2-binding partners due to sequence similarity with Pyk2. Therefore, it has been reported as a dominant-negative regulator to prevent Pyk2 binding with its partners for signaling pathway activation (15) . In the present study, we constructed the lentivirus shuttle vector merged with EGFP for PRNK transfection, and examined the EGFP expression which represented the efficacy of the PRNK transfection. As shown in Fig. 1 , in the control group, EGFP expression was not observed. In the LV (vector)-EGFP control group, EGFP expression was observed at 27 kDa, indicating that the transfection was effective. In the LV-PRNK-EGFP group, EGFP expression was also observed, but it was located at ~52-54 kDa, suggesting it is a compound of PRNK and EGFP.
In a previous study, we observed that the phosphorylation of Pyk2 was inhibited by the CCR7 monoclonal antibody (12) . In the present study, we transiently transfected CCR7 siRNA into SCCHN cells to silence CCR7 (Fig. 2) (16) , and used CCL19 to induce the CCR7 downstream signaling pathway. The results showed that CCL19 induced the phosphorylation of Pyk2, and CCR7 siRNA significantly reduced this phosphorylation, which had a significant difference compare to the CCL19 and scramble siRNA groups (Fig. 3) . These results demonstrated that Pyk2 is a downstream signaling molecule of CCR7. In the LV-EGFP group, the Pyk2 phosphorylation was similar to the CCL19 group, and in the LV-PRNK-EGFP group, the Pyk2 phosphorylation was significantly reduced. In contrast, the total Pyk2 protein expression had no change in these groups. The results demonstrated that PRNK is a competitive inhibitor of Pyk2 constitutional activation, which will not interfere with Pyk2 expression.
Pyk2 regulates CCL19-induced SCCHN cell viability, migration, invasion and adhesion.
Our previous study used cisplatin to induce cell death and demonstrated that CCL19 can promote PCI-4B and PCI-37B cell viability, migration and invasion, and this function can be blocked by CCR7 monoclonal antibody (10, 11, (17) (18) (19) (20) . In the present study, we examined whether Pyk2 is involved in regulating these bioactivities. In the PCI-4B and PCI-37B cell lines, treatment of CCL19 protected the cells from apoptosis (Fig. 4) (19) . Yet, in the PRNK-transfected PCI-4B and PCI-37B cells, the role of CCL19 was blocked, and the apoptosis was significantly increased ~2-3 times in the PCI-4B and PCI-37B cell lines. As a control, the vector transfection group had no significant change. This indicates that PRNK promotes SCCHN cell apoptosis.
As shown in Fig. 5 , following CCL19 treatment, the viability of the PCI-4B and the PCI-37B cells was unaffected (~100-110%), while the viability of the PRNK-transfected PCI-4B and PCI-37B cells was reduced to less than 50%; the difference was significant. As a control, the vector transfection group had no significant change. The results indicated that PRNK can induce cell death.
We also examined the adhesive ability of the SCCHN cells (Fig. 5) . Following CCL19 pretreatment, the adhesion index of the PCI-4B and the PCI-37B cells increased from 30-40% of control condition to ~70%, suggesting that CCL19 promotes SCCHN cell adhesion to fibronectin. In the stable PRNKexpressing PCI-4B and PCI-37B cells, CCL19 played no role in this adhesion induction, and the adhesion index decreased to the control level. This indicates that the interaction between CCL19 and CCR7-induced adhesion was Pyk2-dependent.
A migration assay was next carried out. Following CCL19 induction, the cell migration index of the PCI-4B and PCI-37B cells was >2 times that of the control group (Fig. 6) . PRNK transfection significantly blocked the effect of CCL19 in both cell lines, leading to decreased cell migration to almost baseline level. The invasion index was the same as the migration index, and CCL19-induced invasion was significantly blocked by PRNK transfection. As a control, the vector transfection group had no significant change in migration and invasion.
Pyk2 mediates the expression of E-cadherin and vimentin
induced by CCR7. E-cadherin and vimentin are known to be associated with epithelial-mesenchymal transition (EMT), which is a key point in tumor progression and generally participates in cell migration and invasion. Our previous results demonstrated that CCL19-treated PCI-4B and PCI-37B cells exhibited a significant increase in the level of vimentin protein and a significant decrease in the level of E-cadherin (10) . In the present study, we examined the PRNK-transfected PCI-4B and PCI-37B cells, and found that, with the Pyk2 inaction the CCL19-induced low E-cadherin expression was significantly Figure 6 . The role of Pyk2 in regulating cell migration and invasion in the SCCHN cells. The PCI-4B and PCI-37B cells, PRNK-or vector-transfected PCI-4B and PCI-37B cells were treated with CCL19 (500 ng/ml) for 24 h and cell migration was assessed, while at 36 h cell invasion was assessed. The results are representative of three independent experiments. * p<0.05 compared to the CCL19 group. increased, and the CCL19-induced high vimentin expression was also significantly decreased ( Figs. 7 and 8) . The results supported that the CCR7-mediated E-cadherin and vimentin expression levels in the SCCHN cells were Pyk2-dependent.
Pyk2 inactivation inhibits SCCHN tumorigenesis in vivo.
The subcutaneous model of human SCCHN in nude mice was used to assess the role of Pyk2 in tumorigenesis in vivo. The stable PRNK-expressing PCI-37B and control vector-transfected PCI-37B cells were subcutaneously injected into the breast of male nude mice. Tumor growth curves were obtained. As shown in Fig. 9 , after injection, the PCI-37B cells developed into a tumor mass on day 9 and grew for 27 days. The tumors formed by the control vector-transfected PCI-37B cells exhibited the same growth rate as the control PCI-37B cell group, and reached a volume of ~1.5 cm 3 on day 27. However, the stable PRNK-expressing PCI-37B cells grew slowly in the bodies of the nude mice, and on day 27, only formed small tumors, which were no more than 0.5 cm 3 . There was a significant difference in tumor size between the cells expressing PRNK or the cells that did not. This finding indicates that Pyk2 activity promotes SCCHN tumorigenesis in vivo.
Discussion
Pyk2 is a non-receptor tyrosine kinase which is believed to play a role in transducing extracellular matrix (ECM)-derived survival signals into cells. The functions of Pyk2 are linked to autophosphorylation of their specific tyrosine residues, and then association with different signaling proteins which mediate activation of downstream targets. Thus, modulation of Pyk2 autophosphorylation may affect several intracellular pathways and may participate in a variety of pathological settings (21) . The Pyk2 related non-kinase (PRNK) is a recently described isoform of Pyk2 that encodes part of the COOH-terminal domain of Pyk2 (22) . As a splice variant form of Pyk2, PRNK will interact with some of the Pyk2-binding partners due to sequence similarity with Pyk2. Therefore, it has been reported as a dominant-negative regulator to prevent Pyk2 binding with its partners for signaling pathway activation and PRNK has been used in numerous studies (23) .
In the present study, we constructed stable PRNKexpressing SCCHN cells, and demonstrated the transfection efficacy by examining EGFP. CCR7 siRNA, which induces CCR7 silencing (16) , blocked the Pyk2 phosphorylation induced by CCL19 as well as PRNK, and had no effect on Pyk2 expression. This indicated that Pyk2 phosphorylation was CCR7 activation-dependent. This finding was similar to the results of a previous study (12) .
Squamous cell carcinoma of the head and neck exhibits metastatic potential. Metastasis involves the separation of cells from the primary tumor, migration into the extracellular matrix, blood vessel invasion, adhesion to endothelium and extravasation and growth in a secondary organ (24) . Pyk2 has been reported to widely participate in this process. In hepatocellular carcinoma, overexpression of Pyk2 resulted in an upregulation of colony formation, adhesion toward laminin, cell motility and wound recovery (25) . In malignant glioma, overexpression of Pyk2 stimulated cell migration (22) . Doxorubicin-resistant MCF-7 (MCF-7/Dox) breast cancer cells expressed constitutively active forms of Pyk2 compared with the expression in parental MCF-7 cells. α-naphthoflavone (ANF) is a wellknown chemopreventive agent; its anticancer properties were found to function by inhibition of clonogenic cell survival via de-phosphorylation of FAK, Pyk2 and EGF-induced Akt in MCF-7/Dox cells and tumor xenografts (26) . In a previous study, following induction with CCL19, SCCHN cells exhibited high viability, a low rate of apoptosis, high migratory ability, high invasive ability and adhesion capability (9) (10) (11) 27, 28) . In the present study, we found that the cellular functions mediated by CCL19 were abrogated by PRNK, which competitively inhibited Pyk2 activity, suggesting that Pyk2 widely participates in the CCR7-mediated SCCHN cell survival and metastatic ability. In order to demonstrate this result in vivo, a nude mouse tumor-bearing model was performed. We found that stable PRNK expression in SCCHN cells significantly inhibited tumor growth in nude mice, which supported the in vitro results.
The activity of Pyk2 regulates physiological processes by many target proteins. Our previous study demonstrated that the Pyk2 inhibitor Tyrphostin A9 blocked CCL19-induced STAT3 phosphorylation, and this STAT3 phosphorylation was involved in the migration and invasion of SCCHN cells (11) . CCL19 was also found to decrease E-cadherin expression and increase vimentin expression in SCCHN cells (10) . The constitutive expression of E-cadherin in both normal and cancer cells may help to maintain adherence junctions and subsequently decrease the capacity of cells to invade or migrate through the extracellular matrix (29, 30) . The important role that EMT plays in tumor progression is known to partly depend on dismantling cadherin-mediated cell-cell junctions (31) . Vimentin, the major intermediate filament (IF) protein of mesenchymal cells, is also associated with EMT. In the present study, when Pyk2 was inactivated, low E-cadherin expression was increased and high vimentin expression was decreased, although with CCL19 induction. Therefore, we presumed that E-cadherin and vimentin are downstream target molecules of CCR7-Pyk2, and this signaling pathway may participate in carcinoma cell growth, separation from the primary tumor, migration into the extracellular matrix, invasion into the lymphatic system, adherence to the endothelium and thus achieve metastasis.
Taken together, based on our in vivo and in vitro study, our results support the conclusion that Pyk2 plays a key role in CCR7-mediated regulation of SCCHN cell metastasis and viability. The present study will aid in the understanding of the mechanism involved in the regulation of CCR7 in SCCHN tumorigenesis and progression. Our ultimate aim is to develop therapeutic methods according to our basic research in the near future.
